Search research articles
Contact Us
Filters
Showing results (11-20 of 215) with videos related to
Page
of 22
Sort By:
Nature
|
April 14, 2017
Neurodegenerative disease: Two-for-one on potential therapies
Ke Zhang, Jeffrey D Rothstein
Biological Psychiatry
|
January 16, 2007
Targeting an old mechanism in a new disease-protection of glutamatergic dysfunction in depression
Rita Sattler, Jeffrey D Rothstein
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
December 1, 2010
New treatments in amyotrophic lateral sclerosis
Nicholas Maragakis, Jeffrey D Rothstein
Plos One
|
August 6, 2016
Astroglia in Thick Tissue with Super Resolution and Cellular Reconstruction
Sean J Miller, Jeffrey D Rothstein
Neurobiology of Disease
|
April 2, 2004
Glutamate transporters: animal models to neurologic disease
Nicholas J Maragakis, Jeffrey D Rothstein
Acta Neuropathologica Communications
|
July 20, 2021
The ESCRT-III protein VPS4, but not CHMP4B or CHMP2B, is pathologically increased in familial and sporadic ALS neuronal nuclei
Alyssa N Coyne, Jeffrey D Rothstein
Acta Neuropathologica Communications
|
March 20, 2021
Nuclear lamina invaginations are not a pathological feature of C9orf72 ALS/FTD
Alyssa N Coyne, Jeffrey D Rothstein
Journal of Visualized Experiments : Jove
|
September 27, 2021
Nuclei Isolation and Super-Resolution Structured Illumination Microscopy for Examining Nucleoporin Alterations in Human Neurodegeneration
Alyssa N Coyne, Jeffrey D Rothstein
Nucleus (Austin, Tex.)
|
February 21, 2024
Nuclear pore dysfunction and disease: a complex opportunity
Charlotte M Fare, Jeffrey D Rothstein
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
September 28, 2022
The Evolving Landscape of Motor Neuron Disease Therapeutics
Nicholas J Maragakis, Jeffrey D Rothstein
Page
of 22
Search research articles
Search
Showing results (11-20 of 215) with videos related to
Sort By:
Page
of 22
Nature
|
April 14, 2017
Neurodegenerative disease: Two-for-one on potential therapies
Ke Zhang, Jeffrey D Rothstein
Biological Psychiatry
|
January 16, 2007
Targeting an old mechanism in a new disease-protection of glutamatergic dysfunction in depression
Rita Sattler, Jeffrey D Rothstein
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
December 1, 2010
New treatments in amyotrophic lateral sclerosis
Nicholas Maragakis, Jeffrey D Rothstein
Plos One
|
August 6, 2016
Astroglia in Thick Tissue with Super Resolution and Cellular Reconstruction
Sean J Miller, Jeffrey D Rothstein
Neurobiology of Disease
|
April 2, 2004
Glutamate transporters: animal models to neurologic disease
Nicholas J Maragakis, Jeffrey D Rothstein
Acta Neuropathologica Communications
|
July 20, 2021
The ESCRT-III protein VPS4, but not CHMP4B or CHMP2B, is pathologically increased in familial and sporadic ALS neuronal nuclei
Alyssa N Coyne, Jeffrey D Rothstein
Acta Neuropathologica Communications
|
March 20, 2021
Nuclear lamina invaginations are not a pathological feature of C9orf72 ALS/FTD
Alyssa N Coyne, Jeffrey D Rothstein
Journal of Visualized Experiments : Jove
|
September 27, 2021
Nuclei Isolation and Super-Resolution Structured Illumination Microscopy for Examining Nucleoporin Alterations in Human Neurodegeneration
Alyssa N Coyne, Jeffrey D Rothstein
Nucleus (Austin, Tex.)
|
February 21, 2024
Nuclear pore dysfunction and disease: a complex opportunity
Charlotte M Fare, Jeffrey D Rothstein
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
September 28, 2022
The Evolving Landscape of Motor Neuron Disease Therapeutics
Nicholas J Maragakis, Jeffrey D Rothstein
Page
of 22